Journey Medical (DERM) Cash from Financing Activities (2021 - 2026)

Journey Medical has reported Cash from Financing Activities for 6 years, with the latest figure at $220000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 93.88% year-over-year to $220000.0; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (down 32.21% YoY), and the FY2025 full-year result was $16.2 million, down 4.51% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $220000.0, down from $5.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $19.2 million in Q4 2023, with the low at -$13.1 million in Q2 2023.
• Historically, Cash from Financing Activities has averaged $2.7 million across 5 years, with a median of $1.6 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 11890.99% — and 2024, when it soared 3048.08%.
• Journey Medical's Cash from Financing Activities stood at $948000.0 in 2022, then soared by 1926.37% to $19.2 million in 2023, then slumped by 44.72% to $10.6 million in 2024, then plunged by 48.9% to $5.4 million in 2025, then slumped by 95.95% to $220000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $220000.0 (Q1 2026), $5.4 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.